Response to "Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting"

被引：0
|
作者：
Moore, Maggie [1 ]
Kosmider, Suzanne [1 ,2 ]
Field, Kathryn [1 ,2 ]
Desai, Jayesh [1 ,2 ]
Lim, Lionel [2 ]
Barnett, Frances [2 ]
Gibbs, Peter [1 ,2 ]
机构：
[1] Western Hosp, Dept Oncol, Footscray, Vic 3011, Australia
[2] Royal Melbourne Hosp, Dept Oncol, Parkville, Vic 3050, Australia
来源：
ONCOLOGIST | 2009年 / 14卷 / 01期
关键词：
RANDOMIZED CONTROLLED-TRIAL; COMBINATION CHEMOTHERAPY;
D O I：
10.1634/theoncologist.2008-0222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [41] Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapy
    Yao, Lei
    Zao, Xiao-Long
    Pan, Xiao-Fei
    Zhang, Hao-Gang
    Wang, Fu-Jing
    Qiao, Peng-Fei
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (02) : 104 - 116
  • [42] Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy
    Stathopoulos, GP
    Rigatos, SK
    Malamos, NA
    Stathopoulos, JG
    Thallasinou, P
    Papazachariou, E
    Antoniou, F
    Kondopodis, E
    Xynotroulas, J
    ONCOLOGY REPORTS, 2004, 12 (06) : 1295 - 1300
  • [43] Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer
    Lankiewicz, Silke
    Zimmermann, Silke
    Hollmann, Christiane
    Hillemann, Tina
    Greten, Tim F.
    MOLECULAR ONCOLOGY, 2008, 2 (04) : 349 - 355
  • [44] RESPONSE TO CHEMOTHERAPY OR CHEMOENDOCRINE THERAPY IN PATIENTS WITH ADVANCED BREAST-CANCER PREVIOUSLY TREATED WITH ADJUVANT CHEMOTHERAPY
    KARDINAL, CG
    PERRY, MC
    KORZUN, AH
    WOOD, W
    BREAST CANCER RESEARCH AND TREATMENT, 1985, 6 (02) : 185 - 185
  • [45] Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study
    Sundararajan, V
    Hershman, D
    Grann, VR
    Jacobson, JS
    Neugut, AI
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 173 - 178
  • [46] Colorectal cancer (CRC) KRAS mutational status and response to chemotherapy in absence of influence of epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) therapy.
    Yarom, Nirit
    Boame, Nana
    Gresham, Gillian
    Hill, David
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] Immunogenicity of iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients
    Wang, Hui
    Cao, Chuanping
    Li, Beilei
    Chen, Shaoliang
    Yin, Jun
    Shi, Jing
    Ye, Dan
    Tao, Qun
    Hu, Peisheng
    Epstein, Alan
    Ju, Dianwen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (05) : 677 - 684
  • [48] Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients
    Hui Wang
    Chuanping Cao
    Beilei Li
    Shaoliang Chen
    Jun Yin
    Jing Shi
    Dan Ye
    Qun Tao
    Peisheng Hu
    Alan Epstein
    Dianwen Ju
    Cancer Immunology, Immunotherapy, 2008, 57 : 677 - 684
  • [49] CHANGING MONOCLONAL ANTIBODY KEEPING UNALTERED THE CHEMOTHERAPY REGIMEN IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS): IS EFFICACY MANTAINED?
    Grande, Roberta
    Cianci, Giovanni
    Grassi, Giulia
    Sperduti, Isabella
    Narducci, Filomena
    Gelibter, Alain
    Nuzzo, Carmen
    Mentuccia, Lucia
    Tuzi, Alessandro
    Gamucci, Teresa
    ANNALS OF ONCOLOGY, 2009, 20
  • [50] Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer (mCRC) patients (pts): is efficacy maintained?
    Grande, R.
    Cianci, G.
    Grassi, G.
    Sperduti, I.
    Narducci, F.
    Gelibter, A.
    Nuzzo, C.
    Mentuccia, L.
    Giampaolo, M. A.
    Gamucci, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 338 - 338
12345